GUIDELINES FOR THE USE OF BISPHOSPHONATES IN THE MANAGEMENT OF MALIGNANT BONE DISEASE
|
|
- Laurence Oliver
- 7 years ago
- Views:
Transcription
1 GUIDELINES FOR THE USE OF BISPHOSPHONATES IN THE MANAGEMENT OF MALIGNANT BONE DISEASE 7.1 GENERAL PRINCIPLES * Bisphosphonates are synthetic analogues of pyrophosphate, a natural regulator of bone metabolism found abundantly in bone matrix. They inhibit differentiation of osteoclast precursors and induce osteoclast apoptosis leading to a decrease in bone resorption. 1, 2 * Bisphosphonates may be classified into two main groups: The more potent nitrogen-containing bisphosphonates inhibit osteoclast bone resorption by inhibition of the mevalonate pathway. They include zoledronic acid, disodium pamidronate and ibandronic acid. The less potent non-nitrogen containing bisphosphonates form cytotoxic ATP analogues interfering with cellular metabolism. They include disodium clodronate and disodium etidronate. 1, 2 * Zoledronic acid, disodium pamidronate and ibandronic acid are the most potent and widely used bisphosphonates for the management of metastatic bone disease. 3 * Ibandronic acid is available in oral and intravenous preparations. It is only licensed for the management of metastatic bone disease in patients with metastatic breast cancer. 4, 5 Local policies may dictate which bisphosphonate is available for clinical use. * Bisphosphonates, and in particular the aminobisphosphonates, are known to have a number of side effects. These include a rise in body temperature and accompanying flu-like symptoms that resemble a typical acute phase response. Other side effects include renal toxicity, hypocalcaemia and osteonecrosis of the jaw GUIDELINES Initiation, dosing and duration of treatment * Treatment with opioids and NSAIDs should be optimised before using bisphosphonates for pain relief. Consider referral for radiotherapy or orthopaedic interventions where appropriate. 7 [Level 4] * Bisphosphonates should be considered where clinically appropriate for the prevention of skeletal related events and treatment of malignant bone pain in patients with bone metastases from breast cancer or hormone refractory prostate cancer and in patients with multiple myeloma. 1, 7-9, 10 [Level 1+] Decisions to treat should be based on an assessment of their general medical condition and expected survival time. 11 [Level 4] * In patients with lung, renal or solid tumours (other than breast or prostate) metastasizing to bone, the strongest evidence is for the use of zoledronic acid to delay the onset of skeletal related events. 11 [Level 2] * Zoledronic acid should be the current bisphosphonate of choice for patients with hormone refractory prostate cancer with bone metastases. This is for both prevention of skeletal related events and palliation of bone pain. 6 [Level 2++ ] Page 37
2 * If using zoledronic acid, the datasheet recommends the use of oral calcium supplements 500mg daily plus vitamin D 400 IU daily. This will reduce the risk of hypocalcaemia. Monitoring of serum calcium and phosphate levels is also required. 7, 12 [Level 4] * Sodium clodronate is an alternative for bone pain in patients with breast cancer and myeloma. 7, 8 [Level 2++] Oral administration is often poorly tolerated. It may be given intravenously or subcutaneously. 5, 13 [Level 4] * Ibandronic acid is currently only licensed for the management of bone metastases in patients with metastatic breast cancer. It may be administered orally or intravenously. 4, 14 [Level 4]. It may have a better renal profile than zoledronic acid. 15 [Level 2+] * Patients should be warned of the possibility of a flare of bone pain and transient acute phase reactions characterized by fever and myalgia which occur in 15-30% of patients. These generally occur after the first infusion of nitrogen containing bisphosphonates and less frequently after following infusions. 6 [Level 4] 5, 6, 7, 8, Table 7.1 Use of bisphosphonates in the management of metastatic bone disease 13, 15 [For level see text] Drug Dose Route of Diluent Rate of infusion administration Zoledronic 4mg Intravenously 100ml sodium minutes Acid chloride 0.9% or Repeat every 4 weeks dextrose 5% Disodium 90mg Intravenously ml sodium Rate not exceeding Pamidronate chloride 0.9% 1mg/min Ibandronic 6mg Intravenously 100ml sodium 15 minutes Acid chloride 0.9% or Repeated every 4-6 dextrose 5% 50mg Orally weeks Not applicable Not applicable Sodium 600mg- Intravenously 500ml sodium Depends on dose. Clodronate 1500mg chloride 0.9% or Range 2-4 hours dextrose 5% 4, 7, 13, 14, 16 * If effective, bisphosphonate infusions should be repeated at regular intervals. [Level 4] * A patient who fails to respond to the first dose of a bisphosphonate used for the treatment of pain should, if clinically appropriate, receive a further two consecutive doses at 4-weekly intervals before being considered a non-responder. 7 [Level 2+] * In patients with disease progression in the skeleton and who are experiencing pains despite the use of oral bisphosphonates or disodium pamidronate, changing to zoledronic acid or ibandronic acid can improve pain control. 6 [Level 2+] * Since the risk of skeletal related events is continuous, treatment if tolerated should be continued for at least 2 years, even if a patient experiences a bone event. Continuation of treatment beyond 2 years should be based on an individual risk assessment. 6 [Level 4] * Bisphosphonates should not be discontinued once skeletal events occur (unless for other clinical reasons) as continuing use significantly reduces the risk of subsequent skeletal events. 6 [Level 2+] Page 38
3 * Table 7.1 gives further details of the dosing regimens for the commonly used bisphosphonates Bisphosphonates in renal failure * Hypocalcaemia is a well recognised electrolyte abnormality associated with bisphosphonates. Renal failure and other electrolyte abnormalities, particularly hypomagnesaemia, frequently coexist with hypocalcaemia. 3 [Level 4] * To avoid renal toxicity with bisphosphonates, serum creatinine should be checked and hydration status clinically assessed, prior to each treatment. The serum calcium should also be checked prior to every infusion. 6, 17 [Level 4] * The risk of renal failure is directly related to drug infusion time and dosage. The use of high dose zoledronic acid with a short infusion time is especially nephrotoxic. 3 [Level 4] * Treatment with zoledronic acid and disodium pamidronate should not be initiated in patients with severe renal impairment (Cr Cl<30mls/min) unless in cases of life-threatening hyperalcaemia where the benefits are judged to outweigh the risks. [Level 4] * When using bisphosphonates for the treatment of bone pain, and where there is persistent renal deterioration but a need for treatment, it may be appropriate to consider either a dose reduction or a longer infusion time. Close monitoring is essential. 6 [Level 4] * There is a growing body of evidence showing that ibandronic acid is better tolerated in renal failure compared to other bisphosphonates. 24 [Level 2+] However, dose reduction, monitoring, and longer infusion times are still required if there is severe renal impairment. 20 [Level 4] * Table 7.2 gives details of the bisphosphonate dose adjustments required in renal impairment Osteonecrosis of the jaw (ONJ) 7, 12, 16 * Osteonecrosis of the jaw has been reported in cancer patients whose treatment regimens include intravenous bisphosphonates. A very small number of cases have also been reported in patients receiving oral bisphosphonates for non-cancer indications. Clinical features include exposed bone in the maxillofacial area, which occurs in association with dental surgery or can occur spontaneously, with no evidence of healing. 19, 20, 21 [Level 4] * A working diagnosis is made when there is no evidence of healing after 6 weeks of appropriate evaluation and dental care and no evidence of metastatic disease in the jaw or osteoradionecrosis. If osteonecrosis does occur, invasive dental procedures should be avoided if possible. 19 [Level 4] * Where clinically appropriate, patients should have a dental examination and any dental treatment required before starting bisphosphonate treatment. 3-5, 7, 13, 14, 16, 19 [Level 4] * Patients should be educated regarding the importance of good oral hygiene to reduce the risk of dental infection and periodontal infections. They should be encouraged to advise their dentist they are receiving bisphosphonate treatment. 19 [Level 4] * Length of exposure to bisphosphonates is strongly associated with development of ONJ. It is extremely rare for those patients receiving less than 12 treatments to develop ONJ. Therefore if a patient has a poor prognosis and it is anticipated that they are only going to receive a few infusions for bone pain, dental checks may not be essential or appropriate. 19 [Level 4] * Written information regarding bisphosphonate therapy and preventative measures for ONJ should be made available to patients. 22 [Level 4] * In patients who develop ONJ whilst receiving bisphosphonates, the decision to stop or continue treatment should be made on a case by case basis. Cessation of therapy may not have an effect on established osteonecrosis. Referral to the local dental hospital, an oral surgeon or dental oncologist should be considered for further management. 6, 19 [Level 4] Page 39
4 * Patients receiving bisphosphonates and who have dental problems other than ONJ should receive the least invasive dental treatment. 6 [Level 4] Table 7.2 Dosage adjustments for use of bisphosphonates in patients with impaired renal function 4, 5, 7, 12, 13, 14, 16, 18 [Level 4] Creatinine Zoledronic Disodium Intravenous Oral Intravenous Clearance Acid Pamidronate Ibandronic Ibandronic Sodium (ml/min) Acid Acid Clodronate >60 4mg 90mg over 4-6 6mg over 15 50mg daily mg. hours. minutes mg 90mg over 4-6 6mg over 1 50 mg 25% dose hours. hour. daily. reduction recommended mg 90mg over 4-6 6mg over 1 50mg daily % dose hours. hour. reduction recommended mg 90mg over 4-6 6mg over 1 50 mg 25-50% dose hours. hour. daily. reduction recommended. <30 Not Not 2mg over 1 50 mg Not recommended recommended recommended hour. weekly. especially with unless benefit unless benefit creatinine outweighs outweighs risk. clearance risk. <10ml/min. 7.3 STANDARDS 1. Treatment with opioids and non-steroidal anti-inflammatory agents should be optimised before using bisphosphonates for malignant bone pain. 7 [Grade D] 2. The use of bisphosphonates for the management of malignant bone pain should be clearly documented in the case notes. 22 [Grade D] 3. Subsequent infusions of the bisphosphonate should be given as per the recommended regimen for each drug. 4, 5, 7, 13, 14, 16, 18 [Grade D] 4. A patient who fails to respond to the first dose of a bisphosphonate used for the treatment of pain, should, if clinically appropriate, receive a further two consecutive doses at 4-weekly intervals before being considered a non responder. 7 [Grade B] 5. The serum creatinine and adjusted calcium should be checked prior to each bisphosphonate infusion. 6, 17 [Grade B] 6. Those patients prescribed zoledronic acid should also have calcium and vitamin D supplements prescribed. 12 [Grade D] 7. Patient Information Sheets on the use of bisphosphonates and potential adverse effects should be provided. 22 [Grade D] Page 40
5 7.4 REFERENCES 1. Yuen KY, Shelley M, Sze WM, Wilt T, Mason M. Bisphosphonates for advanced prostate cancer. Cochrane Database of Systematic Reviews 2006, Issue 4. Art. No.: CD DOI: / CD Gralow J, Tripathy D. Managing Metastatic Bone Pain: The Role of Bisphosphonates. J Pain Symptom Manage 2007; 33(4): Tanvetyanon T, Stiff PJ. Management of the adverse effects associated with intravenous bisphosphonates. Ann Oncol 2006; 17: Bondronat Concentrate for solution for infusion. Roche Products Limited. Product Information sheet. Available from: [Last accessed 6 November 2008] 5. Bonefos Capsules. Bayer Plc. Product Information Sheet. Available from: [Last accessed 6 November 2008] 6. Aapro M, Abrahamsson PA, Body JJ, Coleman RE, Colomer R, Costa L et al. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol 2008; 19: Wong R, Wiffen PJ. Bisphosphonates for the relief of pain secondary to bone metastases. Cochrane Database of Systematic Reviews Issue 2. Art No.:CD DOI: / CD Pavlakis N, Schmidt RL, Stockler MR. Bisphosphonates for breast cancer. Cochrane Database of Systematic Reviews 2005, Issue 3. Art. No.: CD DOI: / CD pub2. 9. Djulbegovic B, Wheatley K, Ross J, Clark O, Bos G, Goldschmidt H et al. Bisphosphonates in multiple myeloma. Cochrane Database of Systematic Reviews 2002, Issue 4. Art. No.: CD DOI: / CD Ross JR, Saunders Y, Edmonds PM, Patel S, Broadley KE, Johnston SRD. Systematic review of role of bisphosphonates on skeletal morbidity in metastatic cancer. Br Med J 2003; 327: Rosen LS, Gordon D, Tchekmedyian S, Yanaghihara R, Hirsh V, Krzakowski M et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumours: a phase III double blind randomised trial the Zolendronic Acid Lung Cancer and Other Solid Tumour Groups Study Group. J Clin Oncol 2003; 21(16): Zometa 4mg/5ml Concentrate for solution for infusion. Novartis Pharmaceuticals UK. Ltd. Product Information sheet. Available from: [Last accessed 6 November 2008]. 13. Bonefos Capsules. Summary of Product Characteristics. Available from: [Last accessed 8 November 2009]. 14. Bondronat 50mg Film-coated tablets. Summary of Product Characteristics. Available from: [Last accessed 8 November 2009]. Page 41
6 15. Body JJ, Diel IJ, Tripahy D, Bergstrom B. Intravenous ibandronate does not affect time to renal function deterioration in patients with skeletal metastases from breast cancer: phase III trial results. Eur J Cancer Care 2006; 15(3): Aredia Dry Powder. Novartis Pharmaceuticals UK Ltd. Product information sheet [Last accessed 6 November 2009]. 17. Chang JT, Green L, Beitz J. Renal failure with the use of zoledronic acid. New Engl J Med 2003; 349: Cameron D, Fallon M, Diel I. Ibandronate: Its Role in Metastatic Breast Cancer. Oncologist 2006; 11 (Suppl 1): Weitzman R, Sauter N, Eriksen EF, Tarassoff PG, Lacerna LV, Dias R et al. Critical review: updated recommendations for the prevention, diagnosis and treatment of osteonecrosis of the jaw in cancer patients - May Crit Rev Oncol/Haematol 2007; 62: Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G et al. Osteonecrosis of the jaw after treatment with bisphosphonates: Incidence and risk factors. J Clin Oncol 2005; 23(34): Boonyapakorn T, Schirmer I, Reichart PA, Sturm I, Massenkeil G. Bisphosphonate Induced Osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies. Oral Oncol 2008; 44: Guidelines for the Use of Bisphosphonates in the Management of Malignant Bone Disease. Expert Consensus. November CONTRIBUTORS Lead Contributors Dr G Whyte Specialty Registrar in Palliative Medicine Aintree University Hospitals NHS Foundation Trust Liverpool And Clatterbridge Centre for Oncology NHS Foundation Trust Wirral External Reviewer Dr S O Reilly Consultant in Medical Oncology Clatterbridge Centre for Oncology NHS Foundation Trust Wirral Dr J Smith Consultant in Palliative Medicine Countess of Chester NHS Foundation Trust Chester Dr A Whitfield Consultant in Palliative Medicine Blackpool, Fylde and Wyre Hospitals NHS Foundation Trust Blackpool Page 42
7 Dr C Irvine Associate Specialist in Palliative Medicine Hospice of the Good Shepherd Chester Ms H Thomas Macmillan Palliative Care Nurse Specialist Countess of Chester NHS Foundation Trust Chester Ms C Murray Manager Marie Curie Nursing Services North West Preston Lancashire Page 43
The Role of Bisphosphonates in Multiple Myeloma: 2007 Update Clinical Practice Guideline
The Role of Bisphosphonates in Multiple Myeloma: 2007 Update Clinical Practice Guideline Introduction ASCO convened an Update Committee to review and update the 2002 recommendations for the role of bisphosphonates
More informationTreatment of Myeloma Bone Disease
Treatment of Myeloma Bone Disease James R. Berenson, MD Medical & Scientific Director Institute for Bone Cancer & Myeloma Research West Hollywood, CA Clinical Consequences of Myeloma Bone Disease Pathological
More informationBISPHOSPHONATE RELATED OSTEONECROSIS OF THE JAW (BRONJ) BISPHOSPHONATES AND WHAT HAPPENS TO BONE VINCENT E. DIFABIO, DDS, MS MEMBER OF THE COMMITTEE ON HEALTHCARE AND ADVOCACY FROM THE AMERICAN ASSOCIATION
More informationHow To Take A Bone Marrow Transplant
Drug treatments to protect your bones This information is an extract from the booklet, Bone health. You may find the full booklet helpful. We can send you a copy free see page 5. Contents Bisphosphonates
More informationBisphosphonate therapy. osteonecrosis of the jaw
I overview Bisphosphonate therapy and osteonecrosis of the jaw Authors_Johannes D. Bähr, Prof. Dr Dr Peter Stoll & Dr Georg Bach, Germany _Introduction Fig. 1_Structural formula of pyrophosphate and basic
More informationBone Disease in Myeloma
Bone Disease in Myeloma Boston, Massachusetts Saturday, July 26, 2008 Brian G.M. Durie, M.D. Bone Disease in Myeloma Lytic Lesions Spike Bone Marrow Plasma Cells Collapse of Vertebrae Biology of Myeloma
More informationSUMMARY OF THE RISK MANAGEMENT PLAN (by medicinal product)
PART VI SUMMARY OF THE RISK MANAGEMENT PLAN (by medicinal product) Format and content of the summary of the RMP The summary of the RMP part VI contains information based on RMP modules SI, SVIII and RMP
More informationTHERAPEUTIC EFFICACY AND PHARMACOECONOMICS EVAULATION OF PAMIDRONATE VERSUS ZOLEDRONIC ACID IN MULTIPLE MYELOMA PATIENTS
438 J App Pharm 04(03): 438-452 (2011) Qasim et al., 2011 ORIGINAL ARTICLE THERAPEUTIC EFFICACY AND PHARMACOECONOMICS EVAULATION OF PAMIDRONATE VERSUS ZOLEDRONIC ACID IN MULTIPLE MYELOMA PATIENTS Saima
More informationPeninsula Dental Social Enterprise (PDSE)
Peninsula Dental Social Enterprise (PDSE) Surgical Management of Patients on Bisphosphonates Version 2.0 Date approved: December 2014 Approved by: The Board Review due: December 2015 Page 1 of 10 Clinical
More informationOral Health Care Practitioners Perceptions of Bisphosphonate Related Osteochemonecrosis of the Jaws
Oral Health Care Practitioners Perceptions of Bisphosphonate Related Osteochemonecrosis of the Jaws Student: Kelly Cottrell Preceptor: T Dolan DDS, MPH Mentor: J Nieto MPH, MD, PhD Outline: Background
More informationDRUG NAME: Pamidronate
DRUG NAME: Pamidronate SYNONYM(S): Pamidronate disodium, pamidronic acid, APD, aminohydroxypropylidene bisphosphonate COMMON TRADE NAME(S): AREDIA CLASSIFICATION: Bone metabolism regulator Special pediatric
More informationBone Disease in Myeloma
Bone Disease in Myeloma Washington, DC August 8, 2009 Brian G.M. Durie, M.D. Bone Disease in Myeloma Lytic Lesions Spike Bone Marrow Plasma Cells Collapse of Vertebrae Biology of Myeloma Vascular Cytokines
More informationUnderstanding Bisphosphonate Therapy
Understanding Bisphosphonate Therapy International Myeloma Foundation 12650 Riverside Drive, Suite 206 North Hollywood, CA 91607 USA Telephone: 800-452-CURE (United States and Canada) 818-487-7455 FAX:
More informationRenal toxicity in patients with multiple myeloma receiving zoledronic acid vs. ibandronate: A retrospective medical records review
Original Article Free full text available from www.cancerjournal.net Renal toxicity in patients with multiple myeloma receiving zoledronic acid vs. ibandronate: A retrospective medical records review ABSTRACT
More informationTreating Osteoporosis WITH BISPHOSPHONATES
Treating Osteoporosis WITH BISPHOSPHONATES Who is SIGMA? SIGMA is the Canadian Menopause Society. We are professionals specialized in different areas of post-menopausal women s health care, including family
More informationDocetaxel + Carboplatin + Trastuzumab (TCH) Adjuvant Breast Cancer
Docetaxel + Carboplatin + Trastuzumab (TCH) Adjuvant Breast Cancer Background: A non-anthracycline based regimen for high-risk, HER 2 positive breast cancer in the adjuvant setting (BCIRG 006). Patient
More informationOutcomes of Placing Dental Implants in Patients Taking Oral Bisphosphonates: A Review of 115 Cases
DENTAL IMPLANTS J Oral Maxillofac Surg 66:223-230, 2008 Outcomes of Placing Dental Implants in Patients Taking Oral Bisphosphonates: A Review of 115 Cases Bao-Thy Grant, DDS,* Christopher Amenedo, DDS,
More informationOsteoporosis Medicines and Jaw Problems
Osteoporosis Medicines and Jaw Problems J. Michael Digney, D.D.S. Osteoporosis is a condition that affects over 10 million patients in this country, with the majority of those being post-menopausal women.
More informationBone Disease in Myeloma. St. Petersburg, Russia September 16, 2009
Bone Disease in Myeloma St. Petersburg, Russia September 16, 2009 Bi Brian G.M. GMDurie, M.D. MD Bone Disease in Myeloma Lytic Lesions Spike Bone Marrow Plasma Cells Collapse of Vertebrae Biology of Myeloma
More informationSecondary breast cancer in the bone
Secondary breast cancer in the bone This booklet is for anyone who has been diagnosed with secondary breast cancer in the bone. It describes what secondary breast cancer in the bone is, what the symptoms
More informationClinical Management Guideline Management of locally advanced or recurrent Renal cell carcinoma. Protocol for Planning and Treatment
Protocol for Planning and Treatment The process to be followed in the management of: LOCALLY ADVANCED OR METASTATIC RENAL CELL CARCINOMA Patient information given at each stage following agreed information
More informationNational Pharmaceutical Pricing Authority 3 rd Floor, YMCA Cultural Centre 1 Jai Singh Road New Delhi 110001 File No. 23(01)2014/Div.
Dated 21 st November 2014 NPPA Invites Comments of Pharmaceutical Industry & Trade, Consumer Organisations, Public Health Experts and other Stakeholders on the Recommendations of Tata Memorial Centre under
More informationBone Metastases in Advanced Prostate Cancer
Bone Metastases in Advanced Prostate Cancer a report by Fred Saad, MD, FRCS Centre Hospitalier de l Université de Montréal, Hôpital Notre-Dame, Montreal, Canada DOI: 1.17925/OHR.25...1v Fred Saad, MD,
More informationThe Bisphosphonates: analogs of Pyrophosphate
Bisphosphonates The Bisphosphonates: analogs of Pyrophosphate Alendronate (Fosamax ) Clodronate (Bonefos ) Etidronate (Didrocal ) Ibandronate (Boniva ) Pamidronate (Aredia ) Risedronate (Actonel ) Tiludronate
More informationGuidelines for the Use of Naloxone in Palliative Care in Adult Patients
Guidelines for the Use of Naloxone in Palliative Care in Adult Patients Date Approved by Network Governance May 2012 Date for Review May 2015 Changes between Version 1 and 2 1. Guideline background 2.
More informationWest of Scotland Cancer Network Chemotherapy Protocol. Cisplatin and Pemetrexed for Malignant Mesothelioma (LUWOS 0021)
West of Scotland Cancer Network Chemotherapy Protocol Cisplatin and Pemetrexed for Malignant Mesothelioma (LUWOS 0021) Indication Palliative chemotherapy for malignant mesothelioma of the pleura Eligibility
More informationSummary of treatment benefits
Risk Management Plan PEMETREXED Powder for concentrate for Solution for infusion Pemetrexed is also indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non small cell
More informationBefore, Frank's immune cells could
Before, Frank's immune cells could barely recognize a prostate cancer cell. Now, they are focused on it. Stimulate an immune response against advanced prostate cancer Extend median survival beyond 2 years
More informationLung Pathway Group Nintedanib (Vargatef) in advanced Non-Small Cell Lung Cancer (NSCLC)
Lung Pathway Group Nintedanib (Vargatef) in advanced Non-Small Cell Lung Cancer (NSCLC) Indication: In combination with docetaxel in locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma
More informationUrology Nurse Practitioner Urology Research Nurse Australian Prostate Cancer Research Centre Epworth November 18, 2011
Urology Nurse Practitioner Helen Crowe Urology Nurse Practitioner Urology Research Nurse Australian Prostate Cancer Research Centre Epworth November 18, 2011 Nurse Practitioner Registered nurse who has
More information.org. Metastatic Bone Disease. Description
Metastatic Bone Disease Page ( 1 ) Cancer that begins in an organ, such as the lungs, breast, or prostate, and then spreads to bone is called metastatic bone disease (MBD). More than 1.2 million new cancer
More informationWhat You Need to Know for Better Bone Health
What You Need to Know for Better Bone Health A quick lesson about bones: Why healthy bones matter The healthier your bones The more active you can be Bone health has a major effect on your quality of life
More informationLung Pathway Group Pemetrexed and Cisplatin in Non-Small Cell Lung Cancer (NSCLC)
Indication: NICE TA181 First line treatment option in advanced or metastatic non-squamous NSCLC (histology confirmed as adenocarcinoma or large cell carcinoma) Performance status 0-1 Regimen details: Pemetrexed
More informationKanıt: Klinik çalışmalarda ZYTIGA
mkdpk de Sonunda Gerçek İlerleme! Kanıt: Klinik çalışmalarda ZYTIGA Dr. Sevil Bavbek 5. Türk Tıbbi Onkoloji Kongresi Mart 214, Antalya Endocrine therapies Adrenals Testis Abiraterone Orteronel Androgen
More informationScottish Medicines Consortium
Scottish Medicines Consortium pemetrexed 500mg infusion (Alimta ) No. (192/05) Eli Lilly 8 July 2005 The Scottish Medicines Consortium has completed its assessment of the above product and advises NHS
More informationThe Pharmacological Management of Cancer Pain in Adults. Clinical Audit Tool
The Pharmacological Management of Cancer Pain in Adults Clinical Audit Tool 2015 This clinical audit tool accompanies the Pharmacological Management of Cancer Pain in Adults NCEC National Clinical Guideline
More informationOPG-Fc inhibits ovariectomy-induced growth of disseminated breast cancer cells in bone.
Title of the poster Authors Sheffield Cancer Research Centre University of Sheffield OPG-Fc inhibits ovariectomy-induced growth of disseminated breast cancer cells in bone. Dr Penelope Ottewell Background
More informationCancer Related Issues: Bone Metastases
Cancer Related Issues: Bone Metastases Bronwyn Long, RN, DNP, ACHPN, AOCNS Updated from Hawkins, R. Cancer Related Issues: Bone Metastasis. Pittsburgh, PA: Hospice and Palliative Nurses Association; 2010:
More informationHAWAII BOARD OF MEDICAL EXAMINERS PAIN MANAGEMENT GUIDELINES
Pursuant to section 453-1.5, Hawaii Revised Statutes, the Board of Medical Examiners ("Board") has established guidelines for physicians with respect to the care and treatment of patients with severe acute
More informationPrior Authorization Guideline
Prior Authorization Guideline Guideline: PS Inj - Alimta Therapeutic Class: Antineoplastic Agents Therapeutic Sub-Class: Antifolates Client: PS Inj Approval Date: 8/2/2004 Revision Date: 12/5/2006 I. BENEFIT
More informationEverolimus plus exemestane for second-line endocrine treatment of oestrogen receptor positive metastatic breast cancer
LONDON CANCER NEWS DRUGS GROUP RAPID REVIEW Everolimus plus exemestane for second-line endocrine treatment of oestrogen receptor positive metastatic breast cancer Everolimus plus exemestane for second-line
More information* Sections or subsections omitted from the full prescribing information are not listed
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use RECLAST safely and effectively. See full prescribing information for RECLAST. Reclast (zoledronic
More informationNCCP Chemotherapy Protocol. Afatinib Monotherapy
Afatinib Monotherapy INDICATIONS FOR USE: INDICATION Treatment of Epidermal Growth Factor Receptor (EGFR) TKI- naïve adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)
More informationHydration Protocol for Cisplatin Chemotherapy
Betsi Cadwaladr University Health Version: 1.3 CSPM2 Hydration Protocol for Cisplatin Chemotherapy Date to be reviewed: July 2018 No of pages: 9 Author(s): Tracy Parry-Jones Author(s) title: Lead Cancer
More informationBone lesions due to metastatic disease undermine
Implications of Bone Metastases and the Benefits of Bone-Targeted Therapy Allan Lipton Several cancers, including those originating in the breast, prostate, and lung, exhibit a propensity to metastasize
More informationMetastatic Breast Cancer 201. Carolyn B. Hendricks, MD October 29, 2011
Metastatic Breast Cancer 201 Carolyn B. Hendricks, MD October 29, 2011 Overview Is rebiopsy necessary at the time of recurrence or progression of disease? How dose a very aggressive treatment upfront compare
More informationGuidelines for Management of Renal Cancer
Guidelines for Management of Renal Cancer Date Approved by Network Governance July 2012 Date for Review July 2015 Changes Between Versions 2 and 3 Section 5 updated bullets 5.3 and 5.4 Section 6 updated
More informationHow To Choose A Biologic Drug
North Carolina Rheumatology Association Position Statements I. Biologic Agents A. Appropriate delivery, handling, storage and administration of biologic agents B. Indications for biologic agents II. III.
More informationMedications for Prevention and Treatment of Osteoporosis
1 Medications for Prevention and Treatment of Osteoporosis Osteoporosis is a disease where the strength of bones is less than normal, making them more susceptible to fracture, or breaking, than normal
More informationVersion History. Previous Versions. Drugs for MS.Drug facts box fingolimod Version 1.0 Author
Version History Policy Title Drugs for MS.Drug facts box fingolimod Version 1.0 Author West Midlands Commissioning Support Unit Publication Date Jan 2013 Review Date Supersedes/New (Further fields as required
More informationTreating myeloma. Dr Rachel Hall Royal Bournemouth Hospital
Treating myeloma Dr Rachel Hall Royal Bournemouth Hospital Treatment overview When to treat? Aim of treatment Which treatment? Monitoring response to treatment Prevention of complications What happens
More informationAvastin in breast cancer: Summary of clinical data
Avastin in breast cancer: Summary of clinical data Worldwide, over one million people are diagnosed with breast cancer every year 1. It is the most frequently diagnosed cancer in women 1,2, and the leading
More informationBest supportive care: Do we know what it is?
Best supportive care: Do we know what it is? Angela Boland Rumona Dickson Barbara Jack James Stevenson Edge Hill University Faculty of Health www.liv.ac.uk/lrig Collaborative partners Liverpool Reviews
More informationHow To Take Methotrexate By Injection
How To Take Methotrexate By Injection 1 how long does it take for methotrexate to work for abortion 2 methotrexate 15 mg hair loss 3 methotrexate injection dosage for rheumatoid arthritis 4 order methotrexate
More informationABC of palliative care: Principles of palliative care and pain control
Clinical review ABC of palliative care: Principles of palliative care and pain control Bill O'Neill, Marie Fallon Top Introduction Principles of palliative care Principles of managing cancer... Introduction
More informationGuidelines for Cancer Pain Management in Substance Misusers Dr Jane Neerkin, Dr Chi-Chi Cheung and Dr Caroline Stirling
Guidelines for Cancer Pain Management in Substance Misusers Dr Jane Neerkin, Dr Chi-Chi Cheung and Dr Caroline Stirling Patients with a substance misuse history are at increased risk of receiving inadequate
More informationCytotoxic and Biotherapies Credentialing Programme Module 5
Cytotoxic and Biotherapies Credentialing Programme Module 5 1. Drug Dose Determination 2. Drug Calculations 3. Role of the Second Checker 4. The Checking Process At the completion of this module the RN
More informationBCCA Protocol Summary for Palliative Therapy for Metastatic Breast Cancer using Trastuzumab Emtansine (KADCYLA)
BCCA Protocol Summary for Palliative Therapy for Metastatic Breast Cancer using Trastuzumab Emtansine (KADCYLA) Protocol Code Tumour Group Contact Physician UBRAVKAD Breast Dr Stephen Chia ELIGIBILITY:
More informationChemotherapy Order Assessment and Review
Chemotherapy Order Assessment and Review Contents Introduction... 2 Step 1: Verify Patient Information... 2 Step 2: Confirm Protocol Matches Clinical Indication and Eligibility for Treatment... 2 Step
More informationIndication: Posology: Indication: Posology:
Maklumat tambahan indikasi untuk upload pada laman web Year 2014 Products Approved For Additional Indication (DCA 275 9 Mei 2014) NO PRODUCT (ACTIVE INGREDIENT) 1. 1.1 Trajenta Duo 2.5mg/500mg Film-Coated
More informationPrevention of Osteonecrosis of the Jaw (ONJ) in Patients on Bisphosphonate Therapies
Guideline Department of Health, NSW 73 Miller Street North Sydney NSW 2060 Locked Mail Bag 961 North Sydney NSW 2059 Telephone (02) 9391 9000 Fax (02) 9391 9101 http://www.health.nsw.gov.au/policies/ Prevention
More informationChapter 7: Lung Cancer
Chapter 7: Lung Cancer Contents Chapter 7: Lung Cancer... 1 Small Cell... 2 Good PS + Limited stage... 2 Cisplatin/etoposide... 2 Concurrent chemotherapy + XRT... 2 Good / Intermediate PS... 2 Carboplatin
More informationPHOSPHATE-SANDOZ Tablets (High dose phosphate supplement)
1 PHOSPHATE-SANDOZ Tablets (High dose phosphate supplement) PHOSPHATE-SANDOZ PHOSPHATE-SANDOZ Tablets are a high dose phosphate supplement containing sodium phosphate monobasic. The CAS registry number
More information4.2 Spinal Cord Compression
4.2 Spinal Cord Compression AO Protocol Name: Metastatic Spinal Cord Compression (MSCC) AO Type: Type I (New Cancer), Type III (Cancer Complication) Author: ST Introduction: MSCC can cause irreversible
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. VITAMINE B12 STEROP 1mg/1ml Solution for injection / oral solution. Cyanocobalamin
PACKAGE LEAFLET: INFORMATION FOR THE USER VITAMINE B12 STEROP 1mg/1ml Solution for injection / oral solution Cyanocobalamin Read all of this leaflet carefully before you start using this medicine because
More informationCLINICAL POLICY Department: Medical Management Document Name: Opdivo Reference Number: CP.PHAR.121 Effective Date: 07/15
Page: 1 of 6 IMPORTANT REMINDER This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough review and consideration of generally accepted
More information02 DEPARTMENT OF PROFESSIONAL AND FINANCIAL REGULATION
Effective June 13, 2010 02-313, 02-373, 02-380, 02-383, 02-396 Chapter 21 page 1 02 DEPARTMENT OF PROFESSIONAL AND FINANCIAL REGULATION 313 BOARD OF DENTAL EXAMINERS 373 BOARD OF LICENSURE IN MEDICINE
More informationSubcutaneous Testosterone-Anastrozole Therapy in Breast Cancer Survivors. 2010 ASCO Breast Cancer Symposium Abstract 221 Rebecca L. Glaser M.D.
Subcutaneous Testosterone-Anastrozole Therapy in Breast Cancer Survivors 2010 ASCO Breast Cancer Symposium Abstract 221 Rebecca L. Glaser M.D., FACS Learning Objectives After reading and reviewing this
More informationSafety Information Card for Xarelto Patients
Safety Information Card for Xarelto Patients 15mg Simply Protecting More Patients 20mg Simply Protecting More Patients Keep this card with you at all times Present this card to every physician or dentist
More informationMetastatic breast cancer with secondary tumours: advice for patients and relatives
Metastatic breast cancer with secondary tumours: advice for patients and relatives Metastatic breast cancer means that cancer cells from the original cancer in the breast spreads to other parts of the
More informationGuidelines for the Use of Controlled Substances in the Treatment of Pain Adopted by the New Hampshire Medical Society, July 1998
Guidelines for the Use of Controlled Substances in the Treatment of Pain Adopted by the New Hampshire Medical Society, July 1998 Section I: Preamble The New Hampshire Medical Society believes that principles
More informationby Charles (Chuck) Maack Prostate Cancer Advocate and Mentor Wichita, Kansas Chapter, Us TOO Intl., Inc.
BISPHOSPHONATES & DENTAL CONSIDERATIONS by Charles (Chuck) Maack Prostate Cancer Advocate and Mentor Wichita, Kansas Chapter, Us TOO Intl., Inc. The below is information I have compiled and saved to my
More informationAlison White Devang Rai Richard Chye
Ketamine use in hospice patients before and after the sentinel randomised controlled trial of ketamine in cancer pain: A single centre retrospective review Alison White Devang Rai Richard Chye Overview
More informationDrug Shortage Alert 11/15/2012
Drug Shortage Alert 11/15/2012 Recommendations and information provided in Drug Shortage Alerts are compiled by experts in the field. Practitioners always are advised to consult with staff to ensure response
More informationOctober 2012. We hope that our tool will be a useful aid in your efforts to improve pain management in your setting. Sincerely,
October 2012 he Knowledge and Attitudes Survey Regarding Pain tool can be used to assess nurses and other professionals in your setting and as a pre and post test evaluation measure for educational programs.
More informationMaintenance of abstinence in alcohol dependence
Shared Care Guideline for Prescription and monitoring of Acamprosate Calcium Author(s)/Originator(s): (please state author name and department) Dr Daly - Consultant Psychiatrist, Alcohol Services Dr Donnelly
More informationMETASTASES TO THE BONE
RADIATION THERAPY FOR METASTASES TO THE BONE Facts to Help Patients Make an Informed Decision TARGETING CANCER CARE AMERICAN SOCIETY FOR RADIATION ONCOLOGY WHAT ARE BONE METASTASES? Cancer that starts
More informationPPP 1. Continuation of a medication to ensure continuity of care
PRESCRIBING POLICIES: 4.7 PHARMACIST AUTHORITY The College of Pharmacists of BC Professional Practice Policy (PPP) 58 Medication Management (Adapting a Prescription) became effective April 1, 2009. The
More informationAmerican Association of Oral and Maxillofacial Surgeons Position Paper on Bisphosphonate-Related Osteonecrosis of the Jaws
American Association of Oral and Maxillofacial Surgeons Position Paper on Bisphosphonate-Related Osteonecrosis of the Jaws Approved by the Board of Trustees September 25, 2006 Introduction Bisphosphonate-Related
More informationOsteoporosis Medications
Osteoporosis Medications When does a doctor prescribe osteoporosis medications? Healthcare providers look at several pieces of information before prescribing a bone- preserving or bone- building medication.
More informationJanuary 2013 LONDON CANCER NEW DRUGS GROUP RAPID REVIEW. Summary. Contents
LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Paclitaxel albumin (Abraxane ) as a substitute for docetaxel/paclitaxel for cancer Paclitaxel albumin (Abraxane ) as a substitute for docetaxel/ paclitaxel for
More informationMichigan Guidelines for the Use of Controlled Substances for the Treatment of Pain
Michigan Guidelines for the Use of Controlled Substances for the Treatment of Pain Section I: Preamble The Michigan Boards of Medicine and Osteopathic Medicine & Surgery recognize that principles of quality
More informationMultiple Myeloma s Impact on Bones
A Report about Multiple Myeloma s Impact on Bones BONE HEALTH IN FOCUS The significance of bone health in patients with Multiple myeloma Today s patient with cancer faces a daunting amount of information.
More informationNational Horizon Scanning Centre. Vandetanib (Zactima) for advanced or metastatic non-small cell lung cancer. December 2007
Vandetanib (Zactima) for advanced or metastatic non-small cell lung cancer December 2007 This technology summary is based on information available at the time of research and a limited literature search.
More informationRESEARCH IN PALLIATIVE CARE: GOALS AND LIMITATIONS
CAMPUS GROSSHADERN CAMPUS INNENSTADT RESEARCH IN PALLIATIVE CARE: GOALS AND LIMITATIONS Prof. Dr. Claudia Bausewein PhD MSc Research and hospice/palliative care Not new! Emphasis of Cicely Saunders from
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: testing_serum_vitamin_d_levels 9/2015 2/2016 2/2017 2/2016 Description of Procedure or Service Vitamin D,
More informationEnoxaparin for long term anticoagulation in patients unsuitable for oral anticoagulants
Enoxaparin for long term anticoagulation in patients unsuitable for oral anticoagulants Traffic light classification- Amber 2 Information sheet for Primary Care Prescribers Relevant Licensed Indications
More informationAvastin in Metastatic Breast Cancer
Non-interventional study Avastin in Metastatic Breast Cancer ML 21165 / 2007 Clinical Study Report Synopsis ROCHE ML21165 / WiSP Project RH09 / V. 1.0 / 24.06.2013 ROCHE ML21165-2 - Name of Sponsor Roche
More informationGUIDELINES ADJUVANT SYSTEMIC BREAST CANCER
GUIDELINES ADJUVANT SYSTEMIC BREAST CANCER Author: Dr Susan O Reilly On behalf of the Breast CNG Written: December 2008 Agreed at CNG: June 2009 & June 2010 Review due: June 2011 Guidelines Adjuvant Systemic
More informationBCCA Protocol Summary for Palliative Treatment of Advanced Pancreatic Neuroendocrine Tumours using SUNItinib (SUTENT )
BCCA Protocol Summary for Palliative Treatment of Advanced Pancreatic Neuroendocrine Tumours using SUNItinib (SUTENT ) Protocol Code Tumour Group Contact Physician UGIPNSUNI Gastrointestinal Dr. Hagen
More informationOsteoporosis Clinical guideline for prevention and treatment
Osteoporosis Clinical guideline for prevention and treatment Executive Summary Updated November 2014 National Osteoporosis Guideline Group on behalf of the Bone Research Society, British Geriatrics Society,
More informationDrug/Drug Combination: Bevacizumab in combination with chemotherapy
AHFS Final Determination of Medical Acceptance: Off-label Use of Bevacizumab in Combination with Chemotherapy for the Treatment of Metastatic Breast Cancer Previously Treated with Cytotoxic Chemotherapy
More informationLondon Cancer. Mesothelioma Lung Protocols
London Cancer Mesothelioma Lung Protocols Version 0.9 Contents 1. Staging... 3 2. Mesothelioma Summary of Chemotherapy Protocols... 4 3. Mesothelioma Chemotherapy Protocols... 7 3.1. Pemetrexed (Alimta
More informationParacetamol apollo +9191 46 950 950. Paracetamol apollo +9191 46 950 950. Paracetamol
Paracetamol apollo +9191 46 950 950 Paracetamol apollo +9191 46 950 950 Paracetamol CAS Number : 103-90-2 Molecular Weight : 151.17 g/mol Molecular Formula : C8H9NO2 Systematic (IUPAC) : N-(4- hydroxyphenyl)ethanamide
More informationMANAGEMENT OF CHRONIC NON MALIGNANT PAIN
MANAGEMENT OF CHRONIC NON MALIGNANT PAIN Introduction The Manitoba Prescribing Practices Program (MPPP) recognizes the important role served by physicians in relieving pain and suffering and acknowledges
More informationIndication: Indication: Protaxos is indicated in adults.
Maklumat tambahan indikasi untuk upload pada laman web Year 2013 Products Approved For Additional Indication (DCA 262 28 Mac 2013) NO PRODUCT (ACTIVE INGREDIENT) 1. 1.1 EVISTA TABLET 60MG [ Raloxifene
More informationCystic fibrosis and bone health
Cystic fibrosis and bone health Factsheet March 2013 Cystic fibrosis and bone health Introduction As we get older our bones become thinner and weaker, and may become more susceptible to fracture. However
More informationMELATONIN FOR SLEEP DISORDERS IN CHILDREN AND ADOLESCENTS WITH NEURODEVELOPMENTAL DISORDERS SHARED CARE GUIDELINES
MELATONIN FOR SLEEP DISORDERS IN CHILDREN AND ADOLESCENTS WITH NEURODEVELOPMENTAL DISORDERS SHARED CARE GUIDELINES Version control: Version Date Main changes/comments V1 4 June 2013 First draft circulated
More informationNot All Clinical Trials Are Created Equal Understanding the Different Phases
Not All Clinical Trials Are Created Equal Understanding the Different Phases This chapter will help you understand the differences between the various clinical trial phases and how these differences impact
More informationGemcitabine, Paclitaxel, and Trastuzumab in Metastatic Breast Cancer
Gemcitabine, Paclitaxel, and Trastuzumab in Metastatic Breast Cancer Review Article [1] December 01, 2003 By George W. Sledge, Jr, MD [2] Gemcitabine (Gemzar) and paclitaxel show good activity as single
More information